Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.25 (
MEKK1
)
1,856
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have previously linked families with autosomal-dominant, late-onset parkinsonism to chromosome 12p11.2-q13.1 (PARK8). By high-resolution recombination mapping and candidate gene sequencing in 46 families, we have found six disease-segregating mutations (five missense and one putative splice site mutation) in a gene encoding a large, multifunctional protein,
LRRK2
(leucine-rich repeat kinase 2). It belongs to the ROCO protein family and includes a protein kinase domain of the
MAPKKK
class and several other major functional domains. Within affected carriers of families A and D, six post mortem diagnoses reveal brainstem dopaminergic degeneration accompanied by strikingly diverse pathologies. These include abnormalities consistent with Lewy body Parkinson's disease, diffuse Lewy body disease, nigral degeneration without distinctive histopathology, and progressive supranuclear palsy-like pathology. Clinical diagnoses of Parkinsonism with dementia or amyotrophy or both, with their associated pathologies, are also noted. Hence,
LRRK2
may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism.
...
PMID:Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. 1554 3
PD (Parkinson's disease) is an aetiologically heterogeneous disorder characterized by a clinical phenotype consisting of resting tremor, rigidity and bradykinesia. Motor symptoms are associated with a progressive loss of dopaminergic neurons, with Lewy body inclusions within surviving neurons. Although heritability studies have shown evidence of familial aggregation, twin studies have provided limited support for a genetic aetiology. Nevertheless, classical linkage methods have nominated 11 regions of the genome and pathogenic mutations have been identified in several genes, including alpha-synuclein, parkin, ubiquitin C-terminal hydrolase L1, oncogene DJ-1, PTEN-induced protein kinase 1 and microtubule-associated protein tau. Most recently, heterozygous mutations in
LRRK2
(leucine-rich repeat kinase 2) were found to cause late-onset, autosomal-dominant PD. Despite their consistent clinical phenotype, family members with
LRRK2
mutations can have variable alpha-synuclein and tau pathologies. Lrrk2 is a member of the Roc (Ras of complex proteins) family, with Ras GTPase and
MAPKKK
(
mitogen-activated protein kinase kinase kinase
) catalytic domains. Thus its discovery highlights vesicle dynamics and secondary-messenger signalling in disease pathophysiology. To diagnose a disease accurately and effectively treat it, requires an understanding of its molecular pathogenesis. Herein, we provide an overview of the genetics of PD, how these discoveries are revolutionizing long-held beliefs and more importantly how this knowledge may be translated into patient therapy.
...
PMID:Pathophysiology, pleiotrophy and paradigm shifts: genetic lessons from Parkinson's disease. 1604 50
A locus for a dominant form of PD has been mapped to the pericentromeric region of chromosome 12 in a Japanese family. We have confirmed linkage in two families of European ancestry and identified mutations in the gene for
LRRK2
in these two and four additional families with dominantly inherited PD. All mutations are located in highly conserved domains of the gene. The
LRRK2
protein belongs to the ROCO protein family, and includes a ras domaine (ras of complex proteins) and a protein kinase domain of the
MAPKKK
class and several other major functional domains. Within affected carriers of Families A and D, six post-mortem diagnoses reveal brainstem dopaminergic degeneration accompanied by strikingly diverse pathologies. These include abnormalities consistent with Lewy body Parkinson's disease, diffuse Lewy body disease, nigral degeneration without distinctive histopathology and progressive supranuclear palsy-like pathology. Hence,
LRRK2
may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism.
...
PMID:Molecular genetic findings in LRRK2 American, Canadian and German families. 1701 34